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ABSTRACT
Background: Circulating concentrations of biomarkers that are re-
lated to vitamin status vary by factors such as diet, fortification, and
supplement use. Published biomarker concentrations have also been
influenced by the variation across laboratories, which complicates a
comparison of results from different studies.
Objective: We robustly and comprehensively assessed differences in
biomarkers that are related to vitamin status across geographic regions.
Design: The trial was a cross-sectional study in which we investigated 38
biomarkers that are related to vitamin status and one-carbon and trypto-
phan metabolism in serum and plasma from 5314 healthy control subjects
representing 20 cohorts recruited from the United States, Nordic coun-
tries, Asia, and Australia, participating in the Lung Cancer Cohort
Consortium. All samples were analyzed in a centralized laboratory.
Results: Circulating concentrations of riboflavin, pyridoxal
5#-phosphate, folate, vitamin B-12, all-trans retinol, 25-hydroxyvitamin
D, and a-tocopherol as well as combined vitamin scores that were
based on these nutrients showed that the general B-vitamin concen-
tration was highest in the United States and that the B vitamins and
lipid soluble vitamins were low in Asians. Conversely, circulating
concentrations of metabolites that are inversely related to B vitamins
involved in the one-carbon and kynurenine pathways were high in
Asians. The high B-vitamin concentration in the United States ap-
pears to be driven mainly by multivitamin-supplement users.
Conclusions: The observed differences likely reflect the varia-
tion in intake of vitamins and, in particular, the widespread
multivitamin-supplement use in the United States. The results
provide valuable information about the differences in biomarker
1314 Am J Clin Nutr 2017;105:1314–26. Printed in USA.
concentrations in populations across continents. Am J Clin Nutr
2017;105:1314–26.
Keywords: biomarker, Lung Cancer Cohort Consortium, one-carbon
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INTRODUCTION
The quantitative measurement of circulating biomarker con-
centrations has been used in various studies that have investigated
nutritional status, vitamin status, and lifestyle factors in relation
to mortality and morbidities such as cancer and cardiovascular
disease.
Circulating concentrations of vitamins and associated metab-
olites are related to vitamin intakes (1–3), which vary across the
globe because of factors such as diet, lifestyle, vitamin-
enrichment and food-fortification practices, and supplement
use. In some countries, food fortification with various vitamins
has been implemented to correct identified deficiencies or to
reduce disease risk. In the United States, fortification has
become widespread; margarine and milk have been volun-
tarily fortified with vitamins A and D since the 1930s (4, 5),
while enrichment of flour and cereals with thiamin, riboflavin,
and niacin since the 1940s (5) and with folic acid since 1998
(5) has been mandatory. In comparison, other countries gen-
erally have a much more restrictive approach to vitamin fortifi-
cation and have implemented voluntary rather than mandatory
food-fortification strategies. In addition to the mandatory for-
tification strategies in the United States, food manufacturers
often add various vitamins to different food products (6–8),
occasionally at very high concentrations (9), on a discretionary
basis and at times as a marketing approach to promote product
sales. The individual use of vitamin supplements adds to these
geographical differences in vitamin intake from enriched and
fortified foods.
Metabolism of the amino acids methionine (10) and trypto-
phan (11) are dependent on various B vitamins serving as co-
factors. Thus, intakes (12, 13) and circulating concentrations
(14, 15) of B vitamins can also influence the concentrations of
these amino acids and their downstream metabolites.
The performance of different analytical methods used to quantify
biomarkers also varies (16, 17), which has further contributed to the
inherent challenge of comparing results between studies. The use
of a centralized laboratory can overcome such difficulties.
Based on the European analyses that showed inverse relations
between circulating vitamin B-6 [pyridoxal 5#-phosphate (PLP)]39
and methionine and lung cancer risk (18), the Lung Cancer Cohort
Consortium (LC3) was established to prospectively investigate
associations between vitamin B-6, one-carbon metabolites, and
related biomarkers and lung cancer in a large number of cohorts
across different geographic regions. In the current investigation,
we describe circulating concentrations of 38 biomarkers that
are related to vitamin status, one-carbon metabolism (OCM),
and tryptophan metabolism (through the kynurenine pathway)
in the 5314 healthy control subjects from the 20 participating
cohorts of the LC3, which has a total of 10,728 participants
from the United States, Nordic region, Asia, and Australia. The
inclusion of 7 circulating vitamins allowed for the construction
of composite vitamin scores to describe general vitamin status
across geographic regions. All samples underwent identical bio-
chemical analyses with the use of the same analytic assays in a
single laboratory.
METHODS
Study design and population
Information on the participating cohorts, including cohort
acronyms, is shown in Supplemental Methods. Study partici-
pants included the 5364 healthy control subjects from the LC3.
The consortium consisted of 20 cohorts: 11 cohorts from the
United States, 4 cohorts from the Nordic region (Norway,
Sweden, and Finland), 4 cohorts from Asia (Chinese populations
residing in Shanghai or Singapore), and 1 cohort from Australia.
Each cohort contributed 81–513 control participants. Blood
samples (serum or plasma) were collected from 1974 to 2010
(Figure 1). We excluded 50 participants with missing biomarker
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concentrations in plasma or serum samples, which provided a
study population of 5314 participants with a complete data set
(Supplemental Figure 1). Demographic data for the total study
population and each geographic region are shown in Table 1 and,
for each cohort, in Supplemental Table 1. All participants gave
written informed consent to participate in the study. The research
was approved by the institutional review board of the International
Agency for Research of Cancer and each participating cohort.
Multivitamin-supplement use and smoking
Data regarding the self-reported use of multivitamin-
supplements (defined as supplements that contained $3 vita-
mins) were obtained from questionnaires and were coded as
current or no-current use for 12 cohorts and as ever or never for
4 (United States) cohorts (Supplemental Table 1). In the United
States, circulating vitamin concentrations were similar between
subjects who reported current use of multivitamin supplements
and those who reported ever use of multivitamin supplements
(data not shown). Similar vitamin concentrations were also
found for those reporting no-current use compared with those
reporting never use (data not shown). Therefore, we combined
subjects who reported current and ever use into multivitamin-
supplement users and those who reported no-current or never
use into nonusers. No information on multivitamin-supplement
use was available for this study from 2 Nordic and 2 Asian
cohorts and for a varying number of participants in several of the
other cohorts (Supplemental Table 1). Smoking was classified
via self-reports as never, former, or current smoker.
Biochemical analyses
All plasma and serum samples were stored at #2808C from
the time of collection until shipment to the Bevital laboratory
(www.bevital.no) for biochemical analyses. Plasma concentra-
tions of methionine, total homocysteine (tHcy), cystathionine,
total cysteine, serine, glycine, sarcosine, methylmalonic acid (MMA),
tryptophan, and kynurenine were measured with the use of gas
chromatography–tandem mass spectrometry (19). Methionine
sulfoxide (MetSO), choline, betaine, dimethylglycine, creatinine,
arginine, asymmetric dimethylarginine, symmetric dimethylarginine,
homoarginine (20), PLP, pyridoxal, 4-pyridoxic acid, riboflavin,
kynurenic acid, anthranilic acid, 3-hydroxykynurenine (HK),
xanthurenic acid (XA), 3-hydroxyanthranilic acid, quinolinic acid,
cotinine (21), all-trans retinol (vitamin A), 25-hydroxyvitamin D2
[25(OH)D2], 25(OH)D3, a-tocopherol, and g-tocopherol (22) were
analyzed with the use of liquid-chromatography–tandem mass
spectrometry. Folate (23) and vitamin B-12 (24) were determined
by microbiological methods, whereas C-reactive protein was ana-
lyzed with the use of an immunomatrix-assisted laser-desorption
ionization–mass spectrometry (25). A plasma sample was included
as a quality control in all batches.
We modeled the seasonality of circulating 25(OH)D3 separately
for each cohort with the use of a function that included 2 pairs of
sine and cosine functions of the day of blood collection. The sum of
25(OH)D2 and season-adjusted 25(OH)D3 was combined into
season-adjusted total 25(OH)D, which was used as a measure of
vitamin D status. Because methionine may be oxidized to
MetSO during sample storage (26), we used total methionine (i.e.,
methionine plus MetSO) as a measure of circulating methionine
concentrations. The kynurenine-to-tryptophan ratio was calculated
as kynurenine (expressed in nmol/L) divided by tryptophan
(expressed as mmol/L), and the PAr was calculated as 4-pyridoxic
acid:(PLP plus pyridoxal) (27).
Statistical methods
Because most biomarkers were not normally distributed, crude
circulating biomarker concentrations are reported as geometric
means (5th and 95th percentiles). Values of cotinine, which is a
marker of recent nicotine exposure, less than the limit of de-
tection (1 nmol/L) were set to 1 nmol/L (which is well below the
FIGURE 1 Year of blood sample collection. Numbers in each cell indicate the number of samples included from each cohort that year; for the WHI
cohort, this information was not available. ATBC, Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study; CLUE, Campaign Against Cancer and Stroke
and Campaign Against Cancer and Heart Disease; CPS, American Cancer Society Cancer Prevention Study-II Nutrition Cohort; HPFS, Health Professionals
Follow-Up Study; HUNT, Nord-Trøndelag Health Study; MCCS, Melbourne Collaborative Cohort Study; MDCS, Malmo¨ Diet and Cancer Study; MEC,
Multiethnic Cohort; NHS, Nurses’ Health Study; NSHDS, Northern Sweden Health and Disease Study Cohort; NYU, New York University Women’s Health
Study; PHS, Physicians’ Health Study; PLCO, Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial; SCCS, Southern Community Cohort Study;
SCHS, Singapore Chinese Health Study; SCS, Shanghai Cohort Study; SMHS, Shanghai Men’s Health Study; SWHS, Shanghai Women’s Health Study; U.S.,
United States; WHI, Women’s Health Initiative; WHS, Women’s Health Study.
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concentrations in both passive and active smokers) before being
log transformed. Geometric means (95% CIs) by region were
estimated with the use of mixed models that were adjusted for
age, sex, and smoking status (former compared with never;
current compared with never) with the cohort as a random effect.
Between-region spreads of adjusted biomarker geometric means
were calculated as CVs (SD divided by the mean of the geometric
means, expressed as %). In the US region, we also investigated
biomarker concentrations after stratification by multivitamin-
supplement use (by combining current and ever compared with
no-current and never), and prefolate fortification compared with
postfolate fortification (1998). The effect of multivitamin-
supplement use was not investigated for non-US populations
because such information was only available for a low number of
these participants. Geometric means (95% CIs) by cohort were
estimated by adjusting for age, sex, and smoking status (former
compared with never; current compared with never) with the use of
generalized linear models.
We investigated proportional differences at each fifth per-
centile of biomarker distributions across the regions (United
States, Nordic region, Asia, and Australia) by quantile regression
(28). The results were plotted graphically as the percentage of
differences between regions (with the Unites States as the ref-
erence) compared with the metabolite concentrations at each
quantile cutoff. These models were adjusted for age (years) at
blood sampling, sex, smoking (former compared with never;
current compared with never) and cohort.
Patterns in biomarker concentrations across cohorts were
investigated by performing a principal component analysis
(PCA) on a matrix that contained centered and standardized
cohort geometric mean biomarker concentrations from the
generalized linear models. To ensure vitamin B-6 was weighted
in the same way as other biomarkers were weighted, we in-
cluded only one of the analyzed vitamin B-6 forms [i.e., PLP,
which is the most commonly used vitamin B-6 marker (29)] in
the PCA.
ANOVA was used for comparisons of normally distributed
variables, and the Kruskal-Wallis test was used for comparisons
of variables that were not normally distributed. Categorical
variables were compared by using the chi-square test.
We combined individual circulating vitamin concentrations,
which were log transformed, centered and standardized to have a
mean of 0 and SD of 1, into 3 different vitamin scores to obtain
measures of general vitamin status. Thus, the B-vitamin score
(BVS) was obtained as the mean of the transformed concen-
trations of riboflavin, PLP, folate, and vitamin B-12. The
fat-soluble vitamin score (FVS) included vitamin A, 25(OH)D,
and a-tocopherol. The total vitamin score (TVS) combined all
7 vitamins. Each combined vitamin score was again standard-
ized to have a mean of 0 and SD of 1. Only the vitamin E form
a-tocopherol was included in the FVS and TVS because this is
the form that is usually used for the assessment of vitamin E
status (30). Vitamin scores across regions, cohorts, and US
multivitamin-supplement users and nonusers were estimated by
adjusting for age, sex, and smoking as previously described for
biomarker concentrations.
Statistical tests were 2-sided, and significance was determined
at the 0.05 level. Statistical analyses were performed by using
SPSS version 22 forWindows software (SPSS Inc.) and R version
3.2.3 software (http://www.r-project.org; The R Foundation)
[using the lm function, the packages lme4 (31), lmerTest, quantreg,
and prcomp].
RESULTS
Demographics
Demographic data are given in Table 1 and Supplemental
Table 1. Overall, the proportion of women was 45.6%. The
geometric mean age differed across regions [from 59.9 y (Nordic)
to 68.0 y (United States); P , 0.001]. Of the total population,
47.3% were current smokers, ranging from 34.3% of subjects in
the United States to 64.4% of subjects in the Nordic region.
For 30.8% of the total population, information on multivitamin-
supplement use was missing mainly because such data were not
available for this study from several Nordic and Asian cohorts
(Table 1). Of subjects with this information available, 27.2%
reported the use of such supplements, whereas 72.8% reported
no use of such supplements. The prevalence of multivitamin-
supplement use was 36.8% in the United States, 26.8% in the
Nordic region (data available for only 205 participants), 6.9% in
Asians, and 13.3% in Australians.
All samples from the United States were collected from 1985
to 2008 except for a small number of samples (n = 15) from
the Campaign Against Cancer and Stroke and the Campaign
Against Cancer and Heart Disease, which were collected in
1974. For the US-based Women’s Health Initiative cohort, in-
formation on the year of blood sampling for each participant was
not available because of confidentiality concerns. Samples were
collected from Nordic cohorts during 1985–2010, from Asian
cohorts during 1986–2006, and from the Australian cohort
during 1990–1994 (Figure 1). Supplemental Table 2 shows the
crude geometric mean (5th and 95th percentile) biomarker
concentrations for the total population and each geographic re-
gion, whereas Supplemental Tables 3 and 4 show these data for
individual cohorts.
PCA using cohort geometric means
The first 2 PCs (Figure 2) explained a total of 53% (32% and
21%, respectively) of the variation in cohort geometric means
obtained from mixed models. Vitamins (with the exception of
g-tocopherol) were grouped together with negative loadings on
PC2 in the loading plot (Figure 2A). The functional B-vitamin
markers (tHcy, MMA, cystathionine, HK, and HK:XA) and com-
ponents of OCM were located opposite the vitamin group. The
kynurenines (except HK) were also grouped together.
When the loading plots (Figure 2A) and score plots (Figure
2B) that were formed from the first 2 PCs were compared, the US
cohorts were generally located in the same direction from the
origin as the vitamin group and opposite the location of the
functional B-vitamin markers. Asian cohorts were located in
the same direction as the functional B-vitamin markers and OCM
group and opposite the location of the US cohorts, whereas the
Nordic and Australian cohorts were located closer to the center of
the score plot.
PC3 and PC4 (which explained 12% and 8% of the variation in
the data set, respectively) did not provide additional information
about general vitamin concentrations or reveal other clear bio-
marker patterns and, thus, were not investigated further.
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Circulating vitamin scores
Vitamin scores across regions and cohorts are shown in Table
2 and Supplemental Tables 5 and 6, respectively, and are shown
graphically in Supplemental Figure 2. The highest mean BVS
at 0.28 (95% CI: 0.10, 0.46; P , 0.05) was found in the United
States, followed by the Australian (20.09; 95% CI: 20.57,
0.39), Asian (20.25; 95% CI: 20.53, 0.02), and Nordic (20.28;
95% CI: 20.52, 20.03) regions. The FVS was highest at 0.48
(95% CI: 0.23, 0.72) in the Nordic region, followed by the
Australian (0.40; 95% CI:20.08, 0.86), US (0.06; 95% CI:20.11,
0.25), and Asian (20.32; 95% CI: 20.61, 20.07) regions. Across
regions, the highest TVS was observed in the United States.
Biomarkers and metabolites
The adjusted geometric mean (95% CI) biomarker concen-
trations for the geographic regions that were obtained from the
mixed models are provided in Table 2 and for each cohort in
Supplemental Tables 5 and 6. Across regions, the spread (CV) in
adjusted geometric mean biomarker concentration was largest for
folate (39%) and g-tocopherol (38%), whereas the CV was
,10% for 17 of 38 biomarkers. Folate was highest in the United
States compared with in the other regions. Functional B-vitamin
markers (tHcy, MMA, cystathionine, HK, and HK:XA) were
generally high in the Asian region and low in the US region, and
fat-soluble vitamins A, 25(OH)D, and a-tocopherol were higher
in Nordic and Australian regions than in US and Asian regions.
Methionine and downstream OCM biomarkers were generally
highest in the Asian region, whereas tryptophan and kynurenines
were generally lowest in the United States and highest in Asia.
Quantile regression (Figure 3) showed that the entire distri-
butions of PLP and folate and the upper part of the distribution
of riboflavin were elevated in the United States compared with
in the other regions. For tHcy, the entire distribution was lower
in the US and Nordic regions than in the Asian and Australian
regions, whereas the entire distribution of cystathionine was
elevated in Asians. In Asia, the upper ranges of MMA and HK
were higher than those observed in other regions. Compared
with other regions, the distribution of the fat-soluble vitamins A,
25(OH)D, and a-tocopherol were lower in Asia, whereas
g-tocopherol was lower in Australia.
Multivitamin-supplement use, mandatory folate
fortification in the United States
For US multivitamin-supplement users and nonusers, the mean
BVS was 0.80 (95% CI: 0.62, 0.97) and 20.01 (95% CI: 20.18,
0.17), respectively, the FVS was 0.41 (95% CI: 0.24, 0.57) and
20.13 (95% CI: 20.29, 0.03), respectively, and the TVS was 0.74
(95% CI: 0.59, 0.89) and20.06 (95% CI:20.21, 0.08), respectively
FIGURE 2 The first 2 PCs (PC1 and PC2) obtained from the principal component analysis based on centered and standardized geometric mean biomarker
concentrations from all cohorts. The loading plot (A) shows the following colors and corresponding biomarkers: blue, vitamins; black, amino acids; red, one-
carbon metabolites; green, kynurenines; and orange, other biomarkers. Functional B-vitamin markers are marked by light-blue ellipses. The score plot (B)
shows the following colors and corresponding cohorts: black, United States; green, Nordic; blue, Asian; and red, Australian. AA, anthranilic acid; ADMA,
asymmetric dimethylarginine; Arg, arginine; ATBC, Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study; aTOC, a-tocopherol; B12, vitamin B-12;
CLUE, Campaign Against Cancer and Stroke and Campaign Against Cancer and Heart Disease; CPS-II, American Cancer Society Cancer Prevention Study-II
Nutrition Cohort; Creat, creatinine; CRP, C-reactive protein; Cysta, cystathionine; DMG, dimethylglycine; gTOC, g-tocopherol; HAA, 3-hydroxyanthranilic
acid; hArg, homoarginine; HK, 3-hydroxykynurenine; HPFS, Health Professionals Follow-Up Study; HUNT, Nord-Trøndelag Health Study; KA, kynurenic
acid; KTR, kynurenine:tryptophan ratio; Kyn, kynurenine; MCCS, Melbourne Collaborative Cohort Study; MDCS, Malmo¨ Diet and Cancer Study; MEC,
Multiethnic Cohort; MMA, methylmalonic acid; NHS, Nurses’ Health Study; NSHDS, Northern Sweden Health and Disease Study Cohort; NYU, New York
University Women’s Health Study; PAr, 4-pyridoxic acid:(pyridoxal 5#-phosphate plus pyridoxal); PC, principal component; PHS, Physicians’ Health Study;
PLCO, Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial; PLP, pyridoxal 5#-phosphate; QA, quinolinic acid; Ribo, riboflavin; SCCS, Southern
Community Cohort Study; SCHS, Singapore Chinese Health Study; SCS, Shanghai Cohort Study; SDMA, symmetric dimethylarginine, SMHS, Shanghai Men’s
Health Study; SWHS, Shanghai Women’s Health Study; tCys, total cysteine; tHcy, total homocysteine; tMet, total methionine; Trp, tryptophan; vA, vitamin A;
vD, total 25-hydroxyvitamin D; WHI, Women’s Health Initiative; WHS, Women’s Health Study; XA, xanthurenic acid.
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(Table 2). US-based participants who were taking multivitamins had
higher circulating concentrations throughout the concentration
ranges of all vitamins (except for g-tocopherol, which was lower),
and had lower concentrations of all functional B-vitamin markers
compared with US participants who did not use such supplements
(Supplemental Figure 3).
US multivitamin-supplement users had a higher BVS than that
in all other regions, a higher FVS than that of Asians, and a higher
TVS than in Nordic and Asian regions (P, 0.05) (Table 2). PLP
and folate were higher in US multivitamin-supplement users
than in other regions (P , 0.05).
In US participants who were not using multivitamin supple-
ments, the FVS was lower than in the Nordic region and higher
than in Asia, folate was higher than in the Nordic and Asian regions,
and g-tocopherol was higher than in Asia and Australia (P, 0.05)
(Table 2). The mean BVS tended to be slightly higher in US par-
ticipants who were not using multivitamin supplements (20.01;
95% CI: 20.18, 0.17) compared with Nordic and Asian regions
[20.28 (95% CI:20.53,20.03) and20.25 (95% CI:20.53, 0.02),
respectively], although these differences were NS.
In the United States, the circulating geometric mean con-
centration of folate before and after the implementation of the
mandatory folate fortification of flour (1998) was 23.9 nmol/L
(95% CI: 19.1, 29.8 nmol/L) compared with 37.2 nmol/L (95%
CI: 29.6, 46.7 nmol/L) (P , 0.001). No other biomarkers were
different before compared with after folate fortification (data not
shown). For tHcy, the geometric mean was 12.1 mmol/L (95%
CI: 11.1, 13.2 mmol/L) compared with 11.5 mmol/L (95% CI:
10.5, 12.6 mmol/L) (P = 0.84).
Vitamin deficiency
Plasma and serum concentration cutoffs that were used to
indicate vitamin deficiency were 5 nmol/L for riboflavin (14, 32),
20 nmol/L for PLP (29), 5 nmol/L for folate (33), 150 pmol/L for
vitamin B-12 (33), 0.7 mmol/L for vitamin A (34), 30 nmol/L for
25(OH)D (35), and 12 mmol/L for a-tocopherol (36).
Vitamin B-6 deficiency was observed in 16.1% of the total
population (Supplemental Table 7) and ranged from 9.4% in
US participants to 23.5% in Asians. Of the total population,
9.1% were vitamin D deficient with the highest prevalence of
14.7% in the Asian region and the lowest prevalence in Australian
(4.5%) and Nordic (4.8%) regions. For the other vitamins, the
prevalence of deficiency was low. In US multivitamin-supplement
users, the highest prevalence of deficiency was 3.3%, which was
observed for vitamin B-6 and vitamin D, compared with 12.7%
and 9.5%, respectively, in US participants who were not taking
multivitamin supplements.
DISCUSSION
Principal findings
We report circulating concentrations of 38 biomarkers that are
related to vitamin status, one-carbon metabolism, and tryptophan
metabolism in 5314 healthy individuals from 20 cohorts who
represented US, Nordic, Asian, and Australian regions. Bio-
chemical analyses were performed by a single laboratory, which
enabled the direct comparison of biomarker concentrations
across regions and cohorts. Composite vitamin scores that wereTA
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based on serum and plasma vitamin concentrations showed
that the general B-vitamin status was highest in the United States,
and the general vitamin concentration was low in the Asian region.
We observed a high general vitamin status in multivitamin-
supplement users in the United States. Differences in B-vitamin
concentrations were further reflected by the concentrations of one-
carbon and tryptophan metabolites, which serve as functional
markers of B-vitamin status.
Vitamin status across regions
The grouping of the 7 measured vitamins, which reflected
general positive intercorrelations, combined with the similar
location of the US cohorts in the space spanned by the first 2 PCs
from the PCA motivated the construction of circulating vitamin
scores.
The grouping of US cohorts away from Nordic, Asian, and
Australian cohorts in the score plot combined with the grouping
FIGURE 3 Distribution of vitamins and vitamin markers in regions from a quantile regression by 5th, 10th, 15th, 20th, 25th, 30th, 35th, 40th, 45th, 50th,
55th, 60th, 65th, 70th, 75th, 80th, 85th, 90th, and 95th percentiles. The models were adjusted for age, sex, smoking (former compared with never; current
compared with never) and cohort. The y axis in each panel is scaled to show 3 SDs of the distribution of the biomarker in that panel. The vertical line in each
panel indicates the 50th quantile for each group. HK, 3-hydroxykynurenine; HK/XA, 3-hydroxykynurenine:xanthurenic acid; MMA, methylmalonic acid;
PLP, pyridoxal 5#-phosphate; Total 25(OH) vitamin D, 25-hydroxyvitamin D2 plus season-adjusted 25-hydroxyvitamin D3; tHcy, total homocysteine; US,
United States; aTOC, a-tocopherol; gTOC, g-tocopherol.
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of the vitamins in the loading plot probably reflected abundant
fortification, enrichment, and dietary supplementation practices
in the United States. For instance, the BVS was higher in the
United States than in the other regions. The consumption of
fortified foods strongly affects B-vitamin status in the United
States (5, 8) with ready-to-eat cereals, which are a staple food in
the United States, being a major source of many vitamins (37–
40). Furthermore, widespread voluntary fortification practices in
the United States are not bound by strict regulations and legis-
lation, which often result in the fortification of food products
above mandatory concentrations (5).
At the time of blood sampling, vitamin fortification was
much less common in the other regions included in this study,
which is in accordance with the lower vitamin concentrations
that were observed for these regions. Within the Nordic region,
Norway (41) and Sweden (42), fortification was limited to only
vitamins A and D in dairy products, and the consumption of
cod-liver oil provided a further source of vitamin D in Norway
(43), whereas there was no fortification in Finland (44). The
concentrations of vitamins B-2, B-6, folate, and B-12 in the
Nordic cohorts that were included in LC3 were similar to the
concentrations that were previously measured by the same
laboratory in Northern European (Sweden and Denmark) (45)
and Norwegian (14, 46) cohorts. In Asia, China had no vitamin
fortification during the sampling period, whereas Singapore
(47) started fortification with folic acid in 1998, and in Aus-
tralia, only the fortification of cereals with retinol took place
(48). In addition, it has been reported that intake of vitamin A is
low in China (49) compared with in the United States (9, 50).
Low circulating 25(OH)D in Asians (51, 52) was suggested to
be related to skin pigmentation and the cultural avoidance of
sun exposure (52).
Multivitamin-supplement use
The high prevalence of multivitamin-supplement use among
US participants in this study (36.8%) (Table 1) is consistent with
the literature (53, 54) and contributed significantly to the high
B-vitamin status in this region. For populations outside of the
United States in this study, multivitamin-supplement use was less
common, and data were available for only a few of these par-
ticipants. A prevalence of multivitamin-supplement use of 22–
27% in the Nordic countries Sweden and Norway has been
reported (55), similar to the 26.8% shown in the current
study. Because of the limited data available, stratification by
multivitamin-supplement use in Nordic, Asian, and Australian
regions was not performed when modeling vitamin status.
Thus, the vitamin status obtained for each of these regions was
influenced by the inclusion of participants who were not using
supplements as well as subjects who were using supplements.
Despite the reported increases in use of vitamin supplements
over the past decades (56, 57), we found that the year of blood
sample collection was not related to vitamin status (data not
shown). This result might be related to the considerable het-
erogeneity of the participating cohorts or the distribution of
participants over the time span during which blood samples
were collected.
Notably, US multivitamin-supplement users showed distri-
butions in the upper concentration range for all vitamins except
for g-tocopherol, which was lower. A study of middle-aged
Americans showed that supplement users, on average, had
vitamin intakes that were considerably higher than the estimated
average requirements for several vitamins (58). It has also been
reported that, in some US subgroups, supplement use has pro-
vided vitamins that are already consumed in adequate amounts
(9, 59).
B-vitamin status and one-carbon and tryptophan
metabolites
Components of OCM and tryptophan metabolismmay serve as
functional markers of B-vitamin status with inverse relations
observed for tHcy with folate and vitamin B-12 (60); for
cystathionine, serine, HK, and HK:XAwith vitamin B-6 (29); and
for MMA with vitamin B-12 (60). The grouping of OCM bio-
markers HK and HK:XA opposite the B vitamins in the loading
plot was in-line with these established relations and likely
reflected the functions of B vitamins as cofactors of enzymes that
are involved in these metabolic pathways (61). The low con-
centrations of functional markers in the US cohorts were in
accordance with high circulating concentrations of individual B
vitamins. A notable exception was observed for tHcy, and a lack
of strong inverse relations between geometric means of tHcy with
folate across geographic regions in Europe has been reported
(45). In contrast, in studies in homogenous populations, intakes of
folate (12, 62), vitamin B-2 (12), and vitamin B-6 (12) and
circulating concentrations of folate (15, 62), vitamin B-12 (15,
62), vitamin B-2 (15), and vitamin B-6 (15, 62) were inversely
related to serum and plasma tHcy concentrations. A lack of
inverse associations between tHcy and B-vitamin status across
geographical regions may be related to ethnicity, genetics, nu-
tritional, and other lifestyle factors that are known to influence
tHcy (63).
Circulating concentrations of the tryptophan metabolite HK
(3) and the HK:XA ratio (64) have been shown to be functional
markers of vitamin B-6 status, and both markers were inversely
related to PLP across cohorts in the current study. The HK:XA
ratio has been suggested to be a better functional vitamin B-6
marker than HK alone (64), but the HK:XAwas not the lowest
in the United States, which was the population that showed the
highest PLP concentrations. Kynurenines other than HK were
also related, although more weakly than HK was, to circulating
concentrations of riboflavin and PLP in a homogenous Nor-
wegian population (65) and also across cohorts in this study.
However, we did not consistently find the anticipated rela-
tions across regions. Conceivably, as with tHcy, additional
factors may influence circulating concentrations of tryptophan
metabolites.
Strengths and weaknesses
The study has a large sample size, particularly from the United
States. Information on multivitamin-supplement use in the US
cohorts enabled the categorization according to this influential
behavior.
A further strength of thiswork is the use of a single laboratory for
the analyses of all biomarkers andmetabolites. Between-batch CVs
of quality-control samples showed that the variability of the assays
that were used was small (Supplemental Table 8). Inadequate
sample handling or storage will increase serum and plasma
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concentrations of MetSO, choline, and anthranilic acid combined
with decreased methionine, HK, and 3-hydroxyanthranilic acid
(26, 66) and may compromise the usefulness of comparing
specimens from different biobanks. We did not observe bio-
marker concentrations that indicated detrimental sample han-
dling or storage in this study.
Limitations of the study also exist. Because the consortium
was formed to investigate lung cancer, it was oversampled with
regard to the number of smokers. However, all models were
adjusted for smoking. The included Asian cohorts consisted of
Chinese subjects only. Thus, the current data cannot be expected
to be representative of the Asian region. The Australian cohort
was rather small. Information on multivitamin-supplement use
was available for relatively few participants from the Nordic and
Asian regions. Information on the use of single vitamin sup-
plements was available for very few participants and, thus, was
not included in this work. Most participants were middle aged or
older, and the reported data may not be representative of other age
groups. Finally, information on fasting status, which influences
the circulating concentrations of some biomarkers (67), was not
available for all cohorts and, therefore, was not included in the
analyses.
In conclusion, the present study is the first study, to our
knowledge, to robustly and comprehensively investigate vitamin
status as reflected by circulating biomarkers in different regions
from around the globe. Through the quantification of circulating
concentrations of 7 vitamins and 5 functional B-vitamin markers,
we show that B-vitamin status was higher in the United States
than in the Nordic region, Asia, and Australia, whereas vitamin
status, in general, was low in the Asians. The high prevalence of
multivitamin-supplement use is suggested to be a major deter-
minant of the higher B-vitamin status in the United States.
The presented data will be useful when investigating circulat-
ing biomarker concentrations, nutritional status, and risk of
chronic diseases particularly when different regions or populations
are compared.
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